

Review proposal of durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer (TA662)

Rationale for review

1. Durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer (TA662) was published as a terminated appraisal in 2020. NICE was unable to make a recommendation on durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer because AstraZeneca withdrew its evidence submission.
2. AstraZeneca has now asked NICE to review TA662 under the cost-comparison methods, using atezolizumab with carboplatin and etoposide (TA638) as the comparator.

Proposal options

3. This review will produce revised guidance on the use of durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer.
4. To establish whether this review should follow a cost-comparison or cost-utility route, NICE has consulted stakeholders on whether durvalumab is suitable for evaluation as a cost-comparison. NICE's medicines optimisation team has also engaged with medicines and prescribing associates to create a briefing report on the appropriateness of cost comparison.
5. Following this consultation, the review will proceed under the appropriate process until the updated guidance is issued.

Summary of new evidence and implications for review

6. The company has not presented any new evidence for this review. NICE has not reviewed any published literature for durvalumab at this time.

Proposal decision

7. After consideration of the responses to consultation from relevant stakeholders, and of NICE's medicines optimisation team report, this topic will continue as a cost-comparison. This topic has been scheduled into the work programme.

Proposal sign-off

Ian Watson – Associate Director, Technology Appraisals and Highly Specialised Technologies

15 July 2024

Contributors to this paper

Technical Analyst: Tom Palmer

Programme Manager: Gavin Kenny

Appendix 1

Remit of review

To appraise the clinical and cost effectiveness of durvalumab in combination with platinum-based chemotherapy within its marketing authorisation for untreated extensive-stage small cell lung cancer.

The technology

Durvalumab (Imfinzi, AstraZeneca) in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer.

Table 1: PICO framework

| | |
|--------------------------|---|
| Intervention(s) | Durvalumab in combination with etoposide and either carboplatin or cisplatin |
| Population(s) | Adults with untreated extensive-stage small cell lung cancer |
| Comparators | <ul style="list-style-type: none">• Atezolizumab in combination with etoposide and carboplatin |
| Outcomes | The outcome measures to be considered include: <ul style="list-style-type: none">• overall survival• progression-free survival• response rates• adverse effects of treatment• health-related quality of life. |
| Economic analysis | <p>This technology has been selected to be appraised as a cost-comparison.</p> <p>The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared.</p> <p>Costs will be considered from an NHS and Personal Social Services perspective.</p> |

| | |
|--|--|
| <p>Other considerations</p> | <p>Guidance will only be issued in accordance with the marketing authorisation. Where the wording of the therapeutic indication does not include specific treatment combinations, guidance will be issued only in the context of the evidence that has underpinned the marketing authorisation granted by the regulator.</p> |
| <p>Related NICE recommendations</p> | <p>Related technology appraisals:</p> <p>Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (2020) NICE technology appraisals guidance 638.</p> <p>Related technology appraisals in development:</p> <p>Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361] Publication TBC.</p> <p>Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [TS ID 10693] Publication TBC.</p> <p>Serplulimab with chemotherapy for untreated extensive-stage small-cell lung cancer [TS ID 11912] Publication TBC.</p> <p>Related NICE guidelines:</p> <p>Lung cancer: diagnosis and management (2019, updated 2023) NICE guideline NG122.</p> <p>Related quality standards:</p> <p>Lung cancer in adults (2012, updated 2019) NICE quality standard QS17.</p> |
| <p>Related National Policy</p> | <p>The NHS Long Term Plan (2019) NHS Long Term Plan</p> <p>NHS England (2018) NHS manual for prescribed specialist services (2018/2019)</p> <p>NHS England (2017/19) Standard contract for cancer: chemotherapy (adult)</p> |